Key Details
Price
$10.24Annual Revenue
$1.02 BAnnual EPS
-$14.85Annual ROE
-74.67%Beta
3.48Events Calendar
Next earnings date:
Mar 06, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Mar 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
An analyst started following Emergent BioSolutions (NYSE: EBS) stock as the final trading week of 2024 began, and investors responded favorably. H.C. Wainwright's Raghuram Selvaraju is now monitoring Emergent, which has a broad range of revenue sources. Selvaraju suggests that Emergent is well-diversified and operates in various medical areas with strong growth potential.
An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
Emergent BioSolutions (NYSE: EBS) experienced a drop in its stock price on Tuesday following reports of a share sell-off. The sellers are primarily linked to OHA Agency, which gave Emergent a $250 million loan in August. Emergent clarified in its statement that it will not benefit financially from these sales, as it is not involved in the selling process.
Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities.
Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats.
Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago.
BlueOne Card, Inc.(OTCQX: BCRD) a leading fintech provider of payment hub solutions and prepaid cards, announes an agreement to acquire Milennium EBS, Inc.
GREENBELT, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Maryland has approved the following announcement of a proposed class action settlement that would benefit purchasers of Emergent BioSolutions Inc. common stock (NYSE: EBS):
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024.
FAQ
- What is the primary business of Emergent BioSolutions?
- What is the ticker symbol for Emergent BioSolutions?
- Does Emergent BioSolutions pay dividends?
- What sector is Emergent BioSolutions in?
- What industry is Emergent BioSolutions in?
- What country is Emergent BioSolutions based in?
- When did Emergent BioSolutions go public?
- Is Emergent BioSolutions in the S&P 500?
- Is Emergent BioSolutions in the NASDAQ 100?
- Is Emergent BioSolutions in the Dow Jones?
- When was Emergent BioSolutions's last earnings report?
- When does Emergent BioSolutions report earnings?
- Should I buy Emergent BioSolutions stock now?